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Abstract
Background and aims: Leukocytapheresis is an extracorporeal therapy for ulcerative colitis.
However, no large-scale study on leukocytapheresis has been reported. This large-scale, prospective,
observational study aimed to evaluate the treatment outcomes of leukocytapheresis for active
ulcerative colitis in clinical practice.
Methods: Patients with active ulcerative colitis treated with leukocytapheresis using a Cellsorba E
column between May 2010 and December 2012 were enrolled from 116 medical facilities in Japan.
Results: A total of 847 patients were enrolled, and 623 were available for efficacy analysis. Out
of 847 patients, 80.3% of the patients had moderate to severe disease activity, and 67.6% were
steroid refractory. As concomitant medications, 5-aminosalicylic acids, corticosteroids, and
thiopurines were administered to 94.8%, 63.8%, and 32.8% of the patients, respectively. In
addition, infliximab and tacrolimus were concomitantly used in 5.8% and 12.3%, respectively.
Intensive leukocytapheresis (≥4 leukocytapheresis sessions within the first 2 weeks) was used in
N70% of the patients. Adverse events were seen in 10.3% (87/847), which were severe in only 5
patients (0.6%). Any concomitant medications did not increase the incidence of adverse events.
Intensive leukocytapheresis was as safe as the conventional weekly procedure. The overall
clinical remission rate was 68.9% (429/623), and the mucosal healing rate was 62.5% (145/232).
Clinical remission was achieved more frequently and rapidly in the intensive group than in the
weekly group.
Conclusions: This large-scale study indicates that leukocytapheresis, including intensive
procedure, is a safe and effective therapeutic option for active ulcerative colitis.
© 2014 European Crohn's and Colitis Organisation. Published by Elsevier B.V.icense.Open access under CC BY-NC-ND l1. Introduction
Ulcerative colitis (UC) is an inflammatory bowel disease that
mainly affects the mucosa of the colon, causing erosion and
ulceration.1 UC is a chronic disease with repeated relapses and
remissions; its typical clinical symptoms include bloody stools
and abdominal pain. Although the etiology of UC is not fully
understood, inflammatory cytokines produced by leukocytes
(including neutrophils, monocytes, and lymphocytes) that
infiltrate the mucosa of the intestine are considered key
factors in the pathogenesis of the condition.2,3
Conventional medications for active UC typically include
the use of 5-aminosalicylic acid (5-ASA),4,5 but corticosteroids
are often used in patients refractory to 5-ASA.6,7 Corticoste-
roids are effective in many patients, but their long-term use
may result in various adverse effects, including Cushingoid
facies, infections, and osteoporosis.8 Therefore, long-term
use of corticosteroids should be limited.
Leukocytapheresis (LCAP) using a Cellsorba E column
(Asahi Kasei Medical Co., Ltd., Tokyo, Japan), which is filled
with nonwoven polyester fiber, is a blood purification
therapy that exerts anti-inflammatory effects by removing
activated leukocytes or platelets from the peripheral blood
through an extracorporeal circulation.9–12 An open-label
multicenter randomized control study showed that LCAP
with low-dose corticosteroids (26.9 mg/day on average) in
the treatment of active UC had significantly higher efficacy
(29/39, 74%) than high-dose corticosteroids (47.9 mg/day on
average; 14/37, 38%) and had significantly lower (24%)
incidence of adverse events than high-dose steroid treat-
ment (68%).13 In a multicenter, double-blind, prospective,
case–control study with sham apheresis as placebo treat-
ment, the response rate with LCAP was 80% in 19 patients
with active UC, which was significantly higher than that in
the sham group.14 Recently, LCAP has been shown to beeffective not only in the improvement of clinical symptoms
but also in the induction of mucosal healing.15 However, the
numbers of subjects in these studies were small and no
large-scale study evaluating the efficacy and safety of LCAP
has been conducted.
Recently, biological drugs such as infliximab (IFX) and
immunosuppressive drugs such as tacrolimus (Tac) have been
used for treating UC.16–18 The efficacy and safety of LCAP
with concomitant use of these drugs has not been reported.
Furthermore, in Japan, patients were previously only
allowed to receive LCAP once per week. However, the
revision of public insurance coverage in 2010 removed the
restrictions on the frequency of LCAP and has enabled
patients to receive ≥2 LCAP treatments per week (referred
to as intensive LCAP) in clinical practice. However, the
safety and efficacy of intensive LCAP have not been reported
in the literature. Therefore, we conducted a large-scale,
prospective, observational, postmarketing study to evaluate
the treatment outcomes of LCAP, including intensive LCAP,
as currently used in clinical practice.2. Materials and methods
2.1. Study design
This postmarketing study was conducted in accordance with
the Good Postmarketing Study Practice (GPSP) ordinance of
the Japanese Ministry of Health, Labour and Welfare. The
GPSP ordinance is the authorized standard for postmarketing
studies of approved drugs and medical devices in clinical
practice.
Patients were recruited from 116 medical facilities in
Japan between May 2010 and December 2012. To eliminate
any selection bias, a continuous registration method was
Case report form retrieved
n = 847
Assessment for safety
n = 847
Assessment for 
efficacy outcomes
n = 623
Baseline Lichtiger CAI 4 (n = 81)
Concomitant IFX, Tac, or CyA
administration (n = 143)
≤
Figure 1 Study design. CAI, clinical activity index; CyA, cyclo-
sporin; IFX, infliximab; Tac, tacrolimus.
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pating facilities were enrolled. The treatment strategy for
each patient, including the course of LCAP, was determined
by the attending physician. The observation period spanned
from 2 weeks before the first LCAP session to 2 weeks after
the last LCAP session. After the observation period, the
participating physician entered the information in the case
report form (CRF).
2.2. LCAP treatment
LCAP was performed using Cellsorba E, a column filled with
nonwoven polyester fiber that removes leukocytes. LCAP
was performed 5–10 times during the treatment period at a
blood flow rate of 30–50 mL/min and at a blood processing
volume ≥ 30 mL/kg body weight. Intensive LCAP was de-
fined as performing ≥4 LCAP treatments within the first
2 weeks, and weekly LCAP was defined as performing b4
LCAP treatments within the first 2 weeks.
2.3. Assessment of treatment outcomes
The baseline patient information routinely collected for this
study included age, body weight, sex, duration after UC
onset, extent of disease, the presence/absence of cortico-
steroid resistance/dependence, and concomitant medica-
tions. The information recorded about each LCAP session
included the date LCAP was performed, blood processing
volume, and any anticoagulants used. During the observation
period, we measured the leukocyte count, erythrocyte
count, platelet count, hemoglobin level, C-reactive protein
(CRP) level, and erythrocyte sedimentation rate.
Steroid resistance was defined when active UC failed to
respond to a daily systemic corticosteroid dose of 1–1.5 mg/kg
of body weight given over at least 1 week. Steroid dependence
was definedwhen an attempt to taper corticosteroids had been
unsuccessful in patients with active UC.
All adverse events during the observational periods were
recorded for the safety evaluation, and any event in which
association with LCAP could not be disproved was defined
as adverse events of LCAP. Adverse events were coded
according to the Medical Dictionary for Regulatory Activities
(MedDRA/J version 15.1).
The Lichtiger Clinical Activity Index (CAI)19 was recorded
at baseline (before the first LCAP), at the 5th LCAP, and at
2 weeks after the last LCAP session. In addition, the CAI was
recorded at the 3rd, 7th, and 9th LCAP when possible. A
CAI ≤ 4 at 2 weeks after the last LCAP session was defined as
clinical remission. Clinical remission or a decrease in scores
that were at least half of the pre-LCAP value was defined as
clinical improvement. The Endoscopic Index (EI) of the
Disease Activity Index (DAI)20 at baseline and at 2 weeks
after the last LCAP session was recorded in the patients
whose endoscopic findings were available. An EI ≤ 1 or 0 at
2 weeks after the last LCAP session was defined as mucosal
healing.
2.4. Statistical analyses
The Wilcoxon rank sum test for continuous data and Fisher
exact test for categorical data were used to compare patientbackgrounds, adverse events, and efficacy outcomes. A
comparison between the pretreatment and posttreatment
CAI values was performed using the Wilcoxon signed-rank
test. Comparisons of efficacy outcomes between disease
activities and steroid refractory were performed using the
Fisher exact test and Bonferroni correction. The Kaplan–
Meier curves of time (days) to achieve clinical remission
were compared using the log-rank test. The mean times to
remission in the patients who achieved clinical remission
were compared using the Wilcoxon rank sum test. Missing
data were excluded for respective analyses. In all the
statistical analyses, p b 0.05 (2-sided test) was considered
significant.3. Results
3.1. Patients' background and LCAP treatment status
The CRFs of a total of 847 patients were retrieved, and all
the patients were included in the safety assessment. Of the
847 patients, 81 who had a baseline CAI ≤ 4 and 143 who
were concomitantly treated with IFX, Tac, or cyclosporine
(CyA) were excluded; the remaining 623 patients were
eligible for the efficacy outcome assessment (Fig. 1). The
patients' baseline backgrounds and concomitant medica-
tions, and the therapeutic variables of the LCAP treatment
for the 847 and 623 patients are shown in Table 1.
In the 847 patients, steroid-refractory UC patients with
moderate to severe disease were mainly enrolled in this
study, in which LCAP was used across a wide range of
ages. Approximately 95% of the patients were treated
with concomitant 5-ASA. The rates of concomitant use of
corticosteroids (prednisolone or betamethasone via oral
administration or intravenous injection) and thiopurines
(azathioprine or 6-mercaptopurine) were 63.8% and 32.8%,
respectively. The rates of concomitant use of IFX, Tac, and
CyA were 5.8%, 12.3%, and 1.1%, respectively.
The mean number of LCAP treatments performed was
8.4 ± 2.5; the most frequent number of treatments received
was 10 (59.9%), with the next being 5 (13.2%). Intensive
Table 1 Baseline demographic data, concomitant medications, and LCAP treatment status of the 847 patients for the safety
assessment and the 623 patients for the efficacy assessment.
Item Safety assessment
(No. of patients)
Efficacy assessment
(No. of patients)
Age, years 40.6 ± 16.0 [6–88] (847) 41.7 ± 16.2 [11–88] (623)
Body weight, kg 56.8 ± 11.1 [13.3–117.0] (767) 57.3 ± 11.1 [23.0–117.0] (571)
Sex, male/female 57.6% (488/847)/42.4% (359/847) 59.2% (369/623)/40.8% (254/623)
UC duration, years 6.8 ± 7.4 [0.0–64.4] (819) 6.9 ± 7.6 [0.0–64.4] (603)
Lichtiger CAI 9.7 ± 3.7 (847) 10.3 ± 3.1 (623)
Clinical activity
CAI ≤ 4 9.6% (81/847) –
Mild, CAI = 5–6 10.2% (86/847) 11.7% (73/623)
Moderate, CAI = 7–11 48.8% (413/847) 55.5% (346/623)
Severe, CAI ≥ 12 31.5% (267/847) 32.7% (204/623)
Disease extent
Total 57.2% (483/844) 54.8% (340/621)
Left-sided 37.4% (316/844) 39.8% (247/621)
Others 5.3% (45/844) 5.5% (34/621)
Response to corticosteroid
Resistant 31.0% (261/843) 27.7% (172/620)
Dependent 36.7% (309/843) 36.9% (229/620)
Nonrefractory 32.4% (273/843) 35.3% (219/620)
History of corticosteroid administration 76.0% (642/845) 73.8% (458/621)
Concomitant medications
5-ASA 94.8% (803/847) 95.5% (595/623)
Corticosteroids 63.8% (540/847) 62.9% (392/623)
Thiopurine 32.8% (278/847) 31.5% (196/623)
Infliximab 5.8% (49/847) –
Tacrolimus 12.3% (104/847) –
Cyclosporin 1.1% (9/847) –
Laboratory data
Leukocyte count, /mm3 8930.3 ± 3760.6 (815) 8918.5 ± 3828.6 (596)
Erythrocyte count, ×104/mm3 428.5 ± 63.8 (812) 430.2 ± 62.5 (595)
Platelet count, ×104/mm3 33.2 ± 12.0 (812) 33.1 ± 11.9 (595)
Hemoglobin level, g/dL 12.3 ± 2.1 (814) 12.3 ± 2.1 (595)
CRP level, mg/dL 2.3 ± 4.2 (809) 2.4 ± 4.4 (592)
Erythrocyte sedimentation rate, mm/h 34.3 ± 28.1 (473) 36.2 ± 29.5 (333)
LCAP treatment status
Mean number of LCAP sessions 8.4 ± 2.5 (847) 8.6 ± 2.4 (623)
Frequency of LCAP treatment
Weekly 29.5% (236/800) 29.3% (174/594)
Intensive 70.5% (564/800) 70.7% (420/594)
Blood processing volume per weight, mL/kg 44.3 ± 13.7 (760) 44.2 ± 13.5 (567)
Anticoagulant used
Nafamostat masilate 86.2% (715/829) 85.0% (517/608)
Heparin 13.8% (114/829) 15.0% (91/608)
5-ASA, 5-aminosalicylic acid; CAI, Clinical Activity Index; CRP, C-reactive protein; LCAP, leukocytapheresis; UC, ulcerative colitis.
The data shown are percentages (%) or mean ± standard deviation values. In the brackets, the minimum and maximum values are given.
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ulant nafamostat mesilate was used in 86.2% of the patients,
and heparin was used in 13.8%.3.2. Safety
The overall incidence of adverse events was 10.3% (87/847).
The main adverse events observed were headache (2.2%),
nausea (1.4%), and fever (1.3%; Table 2). These adverse events
are commonly associated with extracorporeal circulation.Adverse events related to infections were seen only in 3
patients (0.4%). Almost all the adverse events were mild to
moderate, and all the patients either recovered from the
events or showed significant improvement.
Six severe adverse events were reported in 5 patients
(0.6%). These included deep vein thrombosis (2 patients),
hypotension (1 patient), anaphylactic shock (1 patient),
and infective endocarditis/candidemia (1 patient). All the
patients recovered from these events after appropriate
treatments. Oral corticosteroids were administered to both
patients with deep vein thrombosis. For the patient who
Table 2 Common adverse events (≥0.5%) in the 847
patients.
Adverse event No. of patients (%)
Patients with ≥1 adverse event 87 (10.3)
General disorders and administration
site conditions
Fever 11 (1.3)
Pain in vascular access site 6 (0.7)
Chill 5 (0.6)
Gastrointestinal disorders
Nausea 12 (1.4)
Abdominal pain 4 (0.5)
Nervous system disorders
Headache 19 (2.2)
Vascular disorders
Hypotension 5 (0.6)
Skin and subcutaneous tissue disorders
Rash 5 (0.6)
Investigations
Platelet count decrease 7 (0.8)
Respiratory, thoracic, and
mediastinal disorders
Nasal congestion 6 (0.7)
Respiratory distress 6 (0.7)
Immune system disorders
Anaphylactic shock 4 (0.5)
Table 3 Comparison of the incidence of adverse events.
Item (No. of patients) No. of
patients (%)
p value
Age, years
b65 (772) 81 (10.5) 0.689
≥65 (75) 6 (8.0)
Clinical activity
Mild, CAI = 5–6 (86) 13 (15.1) 0.443
Moderate, CAI = 7–11 (413) 42 (10.2)
Severe, CAI ≥ 12 (267) 24 (9.0)
Concomitant medications
Only 5-ASA (188) 23 (12.2)
Corticosteroids (540) 51 (9.4) 0.266 a
Thiopurines (278) 24 (8.6) 0.213 a
Infliximab (49) 4 (8.2) 0.614 a
Tacrolimus (104) 13 (12.5) 1.000 a
Cyclosporin (9) 2 (22.2) 0.320 a
Frequency of LCAP treatment
Weekly (172) 17 (9.9) 0.109
Intensive (409) 24 (5.9)
Anticoagulant used
Nafamostat masilate
(5770 treatments)
163 treatments (2.8) 0.322
Heparin (1151 treatments) 26 treatments (2.3)
5-ASA, 5-aminosalicylic acid; CAI, Clinical Activity Index; LCAP,
leukocytapheresis.
The p values were calculated using the Fisher exact test.
a Compared with only 5-ASA.
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used as the anticoagulant; after the event, the patient was
able to receive LCAP by changing the anticoagulant to
heparin. An episode of candidemia and infective endocardi-
tis was observed in a 6-year-old male patient, who was also
treated with sulfasalazine, oral corticosteroids, azathio-
prine, and CyA; this suggests that the patient was highly
immunosuppressed. The patient needed a catheter insertion
for vascular access for the LCAP therapy, which could have
also been a cause of infection. Therefore, the infection
might not be due to the leukocyte removal by LCAP. He
recovered after removal of the catheter and antifungal
therapy.
3.3. Factors influencing the safety of LCAP
Table 3 shows the comparisons of the incidence rates of
adverse events between the subgroups of the backgrounds,
concomitant medications, and LCAP treatment status of
the patients. The incidence rate of adverse events in the
patients aged 65 years or older was 8.0% (6/75), which
was not different from that in the patients younger than
65 years. Any concomitant medications, including IFX and
Tac, did not increase the incidence rate of adverse events
compared with the concomitant use of only 5-ASA. The
incidence rate of adverse events was 9.9% (17/172) in the
conventional weekly LCAP group and 5.9% (24/409) in the
intensive LCAP group (≥4 LCAP sessions within the first
2 weeks), indicating an insignificant difference between the
2 groups. In addition, the types of adverse events did not
significantly differ between the groups. With regard to the
anticoagulant used, the incidence rate of adverse eventswas 2.8% (163/5770 treatments) in the nafamostat mesilate
group and 2.3% (26/1151 treatments) in the heparin group;
these rates were not significantly different. No serious
bleeding events were observed in the heparin group.
3.4. Overall efficacy outcomes
The patients' baseline backgrounds and concomitant medi-
cations, and the therapeutic variables of the LCAP treat-
ment for the 623 patients are shown in Table 1. In the
623 patients, the overall rate of clinical improvement was
73.8% (460/623) and the rate of clinical remission was 68.9%
(429/623) at 2 weeks after the last LCAP session (Fig. 2a).
The mean CAI significantly decreased from a baseline level
of 10.3 ± 3.1 to 3.4 ± 3.2 at 2 weeks after the last LCAP session
(p b 0.001; Fig. 2b). In patients who were concomitantly
treated with corticosteroids, the rate of their withdrawal at
2 weeks after the last LCAP session was 13.5% (53/392). In the
patients whose endoscopic findings were available (n = 232),
the mucosal healing rates signified by an EI of 0 and ≤1 were
19.8% (46/232) and 62.5% (145/232), respectively (Fig. 2c).
The backgrounds of the 232 patients were not significantly
different from those of the 623 patients (data not shown).
The clinical remission rates in the patients with mild
(baseline CAI, 5–6), moderate (CAI, 7–11), and severe disease
activities (CAI, ≥12) were 79.5% (58/73), 67.6% (234/346),
and 67.2% (137/204), respectively, showing no significant
difference between the groups. The clinical remission rates in
the steroid-resistant, steroid-dependent, and nonrefractory
patients were 70.9% (122/172), 64.6% (148/229), and 71.2%
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Figure 2 Overall efficacy outcomes of LCAP in the 623 patients.
(a) Clinical improvement and remission rates at 2 weeks after the
last LCAP session. (b) Comparison of the CAI scores between
before and after the LCAP treatments. (c) Mucosal healing rates in
the patients whose endoscopic findings were available (n = 232).
The data shown are mean ± standard deviation values.
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between the groups.
The clinical remission rates in the patients who were
respectively concomitantly treated with IFX, Tac, and CyA
were 69.0% (29/42), 57.1% (56/98), and 44.4% (4/9), respec-
tively. The clinical remission rate was 68.9% (356/517) in the
patients who received nafamostat mesilate as an anticoagu-
lant and 68.1% (62/91) in the patients who received heparin;
no significant difference was found between the 2 groups.
A total of 169 patients were treated with LCAP mono-
therapy (only concomitant use of 5-ASA). Approximately 85%
of the patients had moderate to severe UC. In the 169
patients, clinical improvement and clinical remission were
achieved in 66.9% (113/169) and 62.7% (106/169) of the
patients, respectively (Fig. 3). The mean CAI significantly
decreased from a baseline level of 9.8 ± 3.0 to 3.7 ± 3.3 at
2 weeks after the last LCAP session. In the patients whose
endoscopic findings were available (n = 62), the mucosal
healing rates signified by an EI of 0 and≤1 were 16.1% (10/62)
and 61.3% (38/62), respectively.3.5. Factors influencing the efficacy outcomes
To clearly compare the efficacy outcomes, the patients who
were not able to undergo at least 5 LCAP sessions (n = 42)
were excluded; the remaining 581 patients were further
evaluated to identify factors influencing the efficacy
outcomes after LCAP. The main reasons why the patients
were not able to undergo at least 5 LCAP sessions were
adverse events (35.7%, 15/42), feasibility problems (26.2%,
11/42), and insufficient effect (14.3%, 6/42).
The results of the univariate analyses comparing the
patients' backgrounds, concomitant medications, and ther-
apeutic variables of LCAP between the remission and
nonremission groups are shown in Table 4. The baseline
leukocyte count and the use of intensive LCAP showed
statistically significant differences between the groups. A
multivariate logistic regression analysis including the above-
mentioned 2 significant factors identified intensive LCAP as
the only factor that was significantly related to remission
after LCAP (p = 0.039; odds ratio, 1.524).66.9%
(113/169) 62.7%(106/169)
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Figure 3 Efficacy outcomes of LCAP monotherapy (concom-
itant use of only 5-aminosalicylic acid). The data shown are
mean ± standard deviation values.
Table 4 Comparison of the baseline demographic data, concomitant medications, and LCAP treatment status between the
remission (n = 415) and nonremission (n = 166) groups using a univariate analysis.
Item Remission group
(No. of patients)
Nonremission group
(No. of patients)
p value
Age, years 41.7 ± 16.5 (415) 42.4 ± 15.7 (166) 0.454 a
Body weight, kg 57.4 ± 11.4 (382) 56.7 ± 10.6 (150) 0.438 a
Sex, male/female 61.2%/38.8% (415) 54.8%/45.2% (166) 0.162 b
UC duration, years 7.1 ± 8.0 (400) 6.7 ± 6.8 (162) 0.675 a
Lichtiger CAI 10.1 ± 3.1 (415) 10.6 ± 3.0 (166) 0.104 a
Clinical activity
Mild (CAI = 5–6)/moderate (CAI = 7–11)/
severe (CAI ≥ 12)
13.3%/54.7%/32.0% (415) 8.4%/57.2%/34.3% (166) 0.266 b
Disease extent
Total/left-sided/others 56.0%/38.6%/5.3% (414) 49.1%/44.2%/6.7% (165) 0.309 b
Response to corticosteroid
Resistant/dependent/nonrefractory 29.4%/34.5%/36.2% (412) 26.5%/43.4%/30.1% (166) 0.127 b
History of corticosteroid administration, yes/no 72.7%/27.3% (414) 77.7%/22.3% (166) 0.249 b
Concomitant medications
5-ASA, yes/no 95.4%/4.6% (415) 95.2%/4.8% (166) 1.000 b
Corticosteroids, yes/no 63.9%/36.1% (415) 57.2%/42.8% (166) 0.156 b
Thiopurine, yes/no 32.5%/67.5% (415) 30.1%/69.9% (166) 0.623 b
Laboratory data
Leukocyte count, /mm3 8966.6 ± 3594.6 (400) 8271.0 ± 3685.3 (157) 0.013 a
Erythrocyte count, ×104/mm3 430.9 ± 63.9 (400) 429.5 ± 60.4 (156) 0.590 a
Platelet count, ×104/mm3 33.1 ± 12.0 (400) 31.5 ± 10.9 (156) 0.110 a
Hemoglobin level, g/dL 12.4 ± 2.1 (400) 12.4 ± 2.0 (156) 0.758 a
CRP level, mg/dL 2.5 ± 4.3 (399) 1.5 ± 2.4 (154) 0.439 a
Erythrocyte sedimentation rate, mm/h 37.0 ± 30.8 (218) 33.0 ± 27.5 (90) 0.394 a
LCAP treatment status
Number of LCAP sessions 9.0 ± 1.8 (415) 8.9 ± 2.0 (166) 0.597 a
Intensive/weekly LCAP 73.0%/27.0% (415) 63.9%/36.1% (166) 0.035 b
Blood processing volume per weight, mL/kg 44.7 ± 13.9 (381) 43.8 ± 12.5 (149) 0.731 a
Anticoagulant used
Nafamostat masilate/heparin 84.7%/15.3% (405) 84.8%/15.2% (164) 1.000 b
5-ASA, 5-aminosalicylic acid; CAI, Clinical Activity Index; CRP, C-reactive protein; LCAP, leukocytapheresis; UC, ulcerative colitis.
The data shown are percentages (%) or mean ± standard deviation values.
a Calculated using the Wilcoxon rank sum test.
b Calculated using the Fisher exact test.
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LCAP treatments
Since intensive LCAP was identified as the most significant
factor related to remission after LCAP, we compared the
patients' backgrounds between the weekly and intensive
LCAP groups (Table 5). The comparison showed higher levels
of pretreatment CAI, leukocyte count, platelet count, and
CRP level in the intensive group, suggesting that intensive
LCAP was used in patients with more severe disease activity
and inflammation.
The rate of clinical improvement was significantly higher
(p = 0.005) in the intensive LCAP group (79.7%, 326/409) than
in the weekly LCAP group (68.6%, 118/172). Similarly, the rate
of clinical remission was significantly higher (p = 0.035) in the
intensive group (74.1%, 303/409) than in the weekly group
(65.1%, 112/172; Fig. 4a). In 340 patients who had all the
necessary CAI data to analyze cumulative remission, a
comparison of the cumulative remission rates revealed that
remission was achieved more rapidly in the intensive LCAP
group than in the weekly LCAP group (p b 0.001, log-rank test;Fig. 4b). The mean durations to remission in the weekly and
intensive groups were 27.6 ± 14.6 days and 15.4 ± 8.6 days,
respectively (p b 0.001, Wilcoxon rank sum test). In the
patients whose endoscopic findings were available (n = 222),
the rate of mucosal healing signified by EI ≤ 1 was achieved
more frequently in the intensive LCAP group (67.0%) than in
the weekly LCAP group (50.0%; p = 0.039). Similarly, the rate
of mucosal healing with an EI = 0 was 10.9% in the weekly
group and 23.3% in the intensive group, although these scores
demonstrated no significant differences between the groups
(p = 0.069; Fig. 4c).4. Discussion
The present study was the first large-scale, prospective,
postmarketing study to investigate the treatment outcomes of
LCAP for active UC in the clinical practice setting. We were
able to obtain reliable and important information regarding
the status of LCAP use in current clinical practice, along with
the treatment outcomes of LCAP, including intensive LCAP.
Table 5 Comparison of the baseline patient demographic data and concomitant medications between the weekly (n = 172) and
intensive LCAP groups (n = 409).
Item Weekly group
(No. of patients)
Intensive group
(No. of patients)
p value
Age, years 42.4 ± 16.1 (172) 41.7 ± 16.3 (409) 0.624 a
Body weight, kg 57.7 ± 11.1 (150) 57.0 ± 11.3 (382) 0.506 a
Sex, male/female 62.8%/37.2% (172) 57.9%/42.1% (409) 0.309 b
UC duration, years 7.0 ± 6.9 (164) 7.0 ± 8.0 (398) 0.299 a
Lichtiger CAI 9.7 ± 2.9 (172) 10.5 ± 3.2 (409) 0.010 a
Clinical activity
Mild (CAI = 5–6)/moderate (CAI = 7–11)/severe (CAI ≥ 12) 15.1%/57.0%/27.9%
(172)
10.5%/54.8%/34.7%
(409)
0.136 b
Disease extent
Total/left-sided/others 50.9%/41.5%/7.6%
(171)
55.4%/39.7%/4.9%
(408)
0.351 b
Response to corticosteroid
Resistant/dependent/nonrefractory 22.1%/43.6%/34.3% (172) 31.3%/34.2%/34.5% (406) 0.040 b
History of corticosteroid administration, yes/no 76.7%/23.3% (172) 73.0%/27.0% (408) 0.406 b
Concomitant medications
5-ASA, yes/no 93.6%/6.4% (172) 96.1%/3.9% (409) 0.200 b
Corticosteroids, yes/no 52.9%/47.1% (172) 65.8%/34.2% (409) 0.005 b
Thiopurine, yes/no 36.0%/64.0% (172) 30.1%/69.9% (409) 0.172 b
Laboratory data
Leukocyte count, /mm3 8181.9 ± 3556.7 (166) 9020.4 ± 3637.3 (391) 0.005 a
Erythrocyte count, ×104/mm3 436.2 ± 64.2 (166) 428.1 ± 62.3 (390) 0.092 a
Platelet count, ×104/mm3 30.4 ± 10.1 (166) 33.6 ± 12.3 (390) 0.004 a
Hemoglobin level, g/dL 12.7 ± 2.0 (166) 12.2 ± 2.1 (390) 0.045 a
CRP level, mg/dL 1.3 ± 2.3 (166) 2.6 ± 4.4 (387) b0.001 a
Erythrocyte sedimentation rate, mm/h 26.7 ± 25.6 (83) 39.2 ± 30.7 (225) b0.001 a
5-ASA, 5-aminosalicylic acid; CAI, Clinical Activity Index; CRP, C-reactive protein; LCAP, leukocytapheresis; UC, ulcerative colitis.
The data shown are percentages (%) or mean ± standard deviation values.
a Calculated using the Wilcoxon rank sum test.
b Calculated using the Fisher exact test.
988 Y. Yokoyama et al.There are two types of extracorporeal therapy for treating
active UC, that is, granulocyte and monocyte adsorption
(GMA) and LCAP. GMA is performed using the Adacolumn
(JIMRO Co., Ltd., Takasaki, Japan), which is filled with
cellulose acetate beads, that enables the removal of
granulocytes and monocytes, while LCAP is performed using
the Cellsorba E column, which is filled with nonwoven
polyester fibers that can remove leukocytes including
lymphocytes. Several studies,21–24 including a large-scale
postmarketing study,25 have reported that GMA is a safe and
effective therapy for the treatment of UC. Although a
randomized, double-blind, sham-controlled study of GMA
for active UC did not demonstrate the efficacy for the
induction of clinical remission in patients with moderate to
severe UC, the clinical remission rate in patients with severe
acute disease was significantly higher in the GMA group than
in the sham group.26 As regards to LCAP, an open-label
multicenter randomized control study13 and a double-blind,
prospective, case-controlled study with sham apheresis as
placebo treatment14 demonstrated the safety and efficacy of
LCAP for treating active UC. However, no large-scale
postmarketing study on LCAP has been reported.
LCAP can be performed for a maximum of 10 times under
public insurance coverage in Japan. In the present study, themean number of LCAP treatments performed was 8.4 ± 2.5
and the maximum number of treatments received was 10
(59.9%), suggesting that most of the patients underwent
LCAP 10 times. Intensive LCAP was performed in N70% of the
patients, demonstrating that intensive LCAP is widely
preferred in clinical practice.
LCAP has been considered a safe treatment because it
does not incorporate immunosuppression.13,27–29 In the
present study, the overall incidence rate of adverse events
in the 847 patients was 10.3%, and the main adverse events
were those commonly seen in association with extracorpo-
real circulation itself. Sever adverse events or adverse
events related to infection were extremely rare. In addition,
LCAP is used safely in elderly patients, and intensive LCAP is
considered as safe as weekly LCAP. The findings obtained in
the present study highlight a high safety profile for LCAP.
Although IFX and Tac therapies were shown to be highly
effective for active UC treatment, the incidence of adverse
events was relatively high.16–18 Several studies have reported
that the use of corticosteroids, immunosuppressives, and
anti-tumor necrosis factors as well as their combination
therapies are associated with an increased rate of opportu-
nistic infections in patients with IBD.30,31 In our study, any
concomitant medications, including IFX and Tac, did not
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Figure 4 Efficacy of weekly and intensive LCAP. (a) Compar-
ison of the clinical improvement and remission rates at 2 weeks
after the last LCAP session between the weekly and intensive
LCAP groups, using the Fisher exact test. (b) Kaplan–Meier curve
of the cumulative remission rates in the weekly and intensive
LCAP groups. (c) Mucosal healing rates in the weekly and
intensive LCAP groups.
989Large-scale observational study of leukocytapheresisincrease the incidence of adverse events. Therefore, as a
nonpharmacological treatment strategy, LCAP has the poten-
tial to be a useful treatment option for active UC patients,
without increasing the incidence of adverse events.
With regard to efficacy outcomes, the rates of overall
clinical improvement and clinical remission at 2 weeks after
the last LCAP session were 73.8% and 68.9%, respectively.
These results may reflect the actual outcomes of LCAP as a
treatment strategy in clinical practice and were comparable
with those previously reported.13–15,32In the present study, we included 169 patients who were
treated with LCAP monotherapy (concomitant use of only
5-ASA), in whom a rate of clinical remission of 62.7% was
achieved. Since this study had no control group, we could
not clearly define the efficacy of LCAP based on its results.
However, in a double-blind case–control study with sham
apheresis as placebo treatment, the rate of improvement
was 33% in the sham column group,14 and 10–40% efficacy
rates in terms of placebo effects were achieved in several
trials which treated active UC patients.16–18 Compared with
these results, the results of the LCAP monotherapy in our
study indicate that LCAP is effective for treating active UC
patients with moderate to severe disease activity.
In recent years, the importance of mucosal healing in the
treatment of UC has been reported as a predictive factor
of long-term outcomes.17,33,34 Okuyama et al.15 reported
that mucosal healing, defined as a Mayo endoscopic
subscore ≤ 1 one week after treatment, was achieved in
47% of patients with steroid-free UC and in 33% patients with
steroid-resistant UC using 5 LCAP treatment sessions. In the
present large-scale study, mucosal healing, defined as a DAI
endoscopic subscore ≤ 1, was achieved in 62.5% patients.
Moreover, even with LCAP monotherapy, mucosal healing
was achieved in 61.3% of the patients, indicating that LCAP
can contribute not only to the improvement of clinical
symptoms but also to mucosal healing.
IFX or Tac was concomitantly used with LCAP in 42 and 98
patients, respectively. However, it was difficult to compare
the definitive efficacy of each treatment because the
patients' backgrounds and the timing of initiating the
combined treatments differed between the individual
patients. Subgroup analyses that are categorized according
to patient background and determining the appropriate
timing of initiating the combined treatment should be
performed in future research studies.
We also investigated the factors that influenced the efficacy
outcome of LCAP. In our multivariate logistic regression
analysis, we identified intensive LCAP, but not weekly LCAP,
as the only factor significantly related to remission after LCAP.
Therefore, we extensively compared the efficacy outcomes of
intensive LCAP with those of weekly LCAP. The results from the
comparison of the backgrounds of the patients in the 2 groups
suggest that intensive LCAP was used in patients with more
severe disease. Despite this fact, the rates of clinical
improvement and clinical remission were significantly higher
in the intensive group than in the weekly group. These results
suggest that intensive LCAP ismore effective thanweekly LCAP.
Furthermore, we found that in the intensive LCAP group,
remission was achievedmore rapidly and the time to remission
was almost half as long as that in the weekly LCAP group.
Sakuraba et al.23 demonstrated that the GMA therapy 2 times
a week was associated with a higher rate and more rapid
induction of remission than once a week of GMA therapy. Their
results were consistent with our present findings in LCAP
treatment. In addition, we found that the rate of mucosal
healing was significantly higher in the intensive LCAP group
than in the weekly LCAP group, suggesting that an intensive
approach can improve the clinical and endoscopic efficacy of
LCAP.
Most previous studies on LCAP have used nafamostat
mesilate as the anticoagulant, in accordance with the
original clinical study on LCAP.13 However, in this study,
990 Y. Yokoyama et al.heparin was used in 13.8% of the patients. The rates of
clinical improvement and clinical remission in the patients in
whom heparin was used as the anticoagulant were almost
equivalent to those in the patients in whom nafamostat
mesilate was used. The incidence of adverse events was not
significantly different between the 2 groups. Thus, the use
of heparin can be feasible in terms of its effects on the
efficacy and safety of LCAP.
The present study had several limitations. Since this
was an observational postmarketing study, a common and
predesigned treatment strategy was absent. A properly
designed randomized controlled study is required to precisely
compare the clinical efficacy between weekly and intensive
LCAP. The results regarding mucosal healing might be biased
because mucosal healing was investigated only in the patients
whose endoscopic findings were available. However, the
strength of this study is the large number of patients, which
makes the results relevant to daily clinical practice.35
In conclusion, for the first time, we investigated the
treatment outcomes of LCAP for patients with active UC in
clinical practice using a large-scale, prospective study.
Steroid-refractory UC patients with moderate to severe
disease were mainly enrolled in this study. The overall rate
of adverse events was 10.3% (87/847). Any concomitant
medications and anticoagulants used did not increase the
incidence of adverse events. Intensive LCAP can be as safe as
weekly LCAP. The low incidence of adverse events of LCAP,
including intensive LCAP, highlighted the safety profile of
the procedure. The overall clinical remission rate was 68.9%,
and the mucosal healing rate was 62.5% at 2 weeks after the
last LCAP session, reflecting the actual outcome of LCAP as a
treatment strategy in clinical practice. Superior efficacy,
including remission rate, was encountered with intensive
LCAP compared with weekly LCAP. Therefore, we conclude
that LCAP, including intensive LCAP, is a safe and effective
therapeutic option for active UC.Conflict of interest
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